Lentiviral Gene Therapy for Cystic Fibrosis: A Promising Approach and First-in-Human Trial.
Davies JC. et al, (2024), Am J Respir Crit Care Med, 210, 1398 - 1408
Pharmacological and pre-clinical safety profile of rSIV.F/HN, a hybrid lentiviral vector for cystic fibrosis gene therapy.
Moiseenko A. et al, (2024), Eur Respir J
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance.
Nesic K. et al, (2024), Mol Cancer, 23
Novel Buffer Formulations for Improved Recombinant Lentiviral Vector Stability and In Vivo Delivery to the Murine Lungs
Miah KM. et al, (2023), MOLECULAR THERAPY, 31, 760 - 760
Type I interferon receptor signalling deficiency results in dysregulated innate immune responses to SARS-CoV-2 in mice.
Ogger PP. et al, (2022), Eur J Immunol, 52, 1768 - 1775
Sendai F/HN pseudotyped lentiviral vector transduces human ciliated and non-ciliated airway cells using α 2,3 sialylated receptors.
Munday RJ. et al, (2022), Mol Ther Methods Clin Dev, 26, 239 - 252
Correction of a chronic pulmonary disease through lentiviral vector-mediated protein expression.
Lund-Palau H. et al, (2022), Mol Ther Methods Clin Dev, 25, 382 - 391
Lung directed antibody gene transfer confers protection against SARS-CoV-2 infection.
Du Y. et al, (2022), Thorax
Intranasal Lentiviral Vector-Mediated Antibody Delivery Confers Reduction of SARS-CoV-2 Infection in Elderly and Immunocompromised Mice.
Du Y. et al, (2022), Front Immunol, 13
Optimisation of lentiviral vectors for gene therapy of pulmonary fibrosis
Dickinson P. et al, (2022), HUMAN GENE THERAPY, 33, A197 - A198
Preclinical optimisation of lentiviral gene therapy delivery for surfactant deficiencies in piglets
McDougall C. et al, (2022), HUMAN GENE THERAPY, 33, A196 - A196
Aerosol-Mediated Non-Viral Lung Gene Therapy: The Potential of Aminoglycoside-Based Cationic Liposomes.
Le Gall T. et al, (2021), Pharmaceutics, 14
Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection
Antepowicz A. et al, (2021), Scientific Reports, 11
Genomic diversity of SARS-CoV-2 in Oxford during United Kingdom's first national lockdown.
Munis AM. et al, (2021), Sci Rep, 11
Identification of LZTFL1 as a candidate effector gene at a COVID-19 risk locus.
Downes DJ. et al, (2021), Nat Genet, 53, 1606 - 1615
RNA-Seq Analysis of the Human Surfactant Air-Liquid Interface Culture Reveals Alveolar Type II Cell-like Transcriptome
Munis AM. et al, (2021), Molecular Therapy - Methods & Clinical Development
A human surfactant B deficiency air-liquid interface cell culture model suitable for gene therapy applications
Munis AM. et al, (2021), Molecular Therapy - Methods and Clinical Development, 20, 237 - 246
DEVELOPMENT OF PROTOCOLS FOR MOUSE GLP-TOXICOLOGY STUDIES
Sinadinos A. et al, (2021), THORAX, 76, A32 - A32